Results 161 to 170 of about 7,423,179 (348)
Molecular Oncology, EarlyView.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
Effects of chemical warfare on hematological indices in chemical agents victims
طب جانباز, 2010 Background and Purpose : The injury of chemical warfare was one of great problem in soldiers and other people in our country. Unfortunately, we do not have any data for delayed effects of these agents. Thus in this study we examine the effect of chemical
T. Amiriani +6 more
doaj
Molecular Oncology, EarlyView.Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon +9 more
wiley +1 more source
Energy-Dense High-Fat/High-Sucrose Diet to Induce Type 2 Diabetes Mellitus in BALB/c Mice Without Genetic Modifications and Chemical Agents. [PDF]
Biology (Basel)Diaz-Herreros AN +7 more
europepmc +1 more source
Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma
Molecular Oncology, EarlyView.PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga +2 more
wiley +1 more source
A Low-Waste Electrospray Method for Applying Chemicals and Finishing Agents to Textiles Zh
, 1999 D.A. Alexander, X. Zhang
openalex +2 more sources
Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Responses of α-amylase and protease activity to chemical agents and metallic salts in barley seeds (Hordeum vulgare L.). [PDF]
HeliyonHossain A +4 more
europepmc +1 more source